Contribution of [18F]DPA-714 PET for Grading and Exploration of the Inflammatory Microenvironment of Glioma.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

NA

Study Classification

INTERVENTIONAL

Study Start Date

2023-10-01

Study Completion Date

2025-04-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The 18-kDa translocator protein (TSPO) is a mitochondrial protein that is weakly expressed in the healthy brain. However, there is an increase in the expression of TSPO in glial tumors. It is even associated with a higher malignancy and a shorter survival of patients. Among the different TSPO ligands, the most commonly used tracers in PET imaging are \[18F\]DPA-714 and 18F-GE180. We hypothesize that \[18F\]DPA-714 PET could improve the current performance for tumor grade definition in vivo, which is a major issue for the therapeutic management of gliomas.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

FDOPA-PET/MRI for the Pre-operative Evaluation of Gliomas

NCT02371031

Glioma Malignant Glioma

TERMINATED PHASE1

The Utility of 18F-DOPA-PET in the Treatment of Recurrent High-grade Glioma

NCT03242824

Glioma

COMPLETED PHASE2

18F-DOPA-PET in Planning Surgery in Patients With Gliomas

NCT02020720

Malignant Glioma Recurrent Brain Neoplasm

COMPLETED EARLY_PHASE1

Evaluation of FLT PET and MRI as Imaging Biomarkers of Early Treatment Response in Patients With Glioblastoma

NCT01880008

Glioblastoma

COMPLETED

68Ga-P16-093 PET/CT Imaging in Glioma Patients

NCT05569434

Glioma

UNKNOWN PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glioma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

[18F]DPA-714 PET

Group Type EXPERIMENTAL

[18F]DPA-714

Intervention Type DRUG

Participant received one injection of 200 MBq of \[18F\]DPA-714

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

[18F]DPA-714

Participant received one injection of 200 MBq of \[18F\]DPA-714

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age greater than or equal to 18 years
* Suspicion of an operable diffuse glioma
* Written informed consent (signed)
* Affiliated or beneficiary of a social security plan

Exclusion Criteria

* Suspicion of grade I glioma
* Surgical urgency (less than 8 days between the suspected diagnosis and surgery)
* Pregnant or breastfeeding woman
* Persons deprived of liberty or under guardianship
* Impossibility to undergo the medical follow-up of the trial for geographical, social or psychological reasons

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No